Novavax, Inc. financials
Key figures from Novavax, Inc.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $57M | $239M | -76.3% |
| Net income | -$53M | $107M | -150.1% |
| Gross margin | 74.9% | 93.6% | -18.7 pts |
| Operating margin | -96.8% | 42.2% | -139.1 pts |
| Net margin | -94.2% | 44.5% | -138.7 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $1.1B | $440M | 39.2% | — | $2.58 |
| FY Dec 2024 | $682M | -$187M | -27.5% | — | -$1.23 |
| FY Dec 2023 | $984M | -$545M | -55.4% | — | -$5.41 |
| FY Dec 2022 | $2.0B | -$658M | -33.2% | — | -$8.42 |
| FY Dec 2021 | $1.1B | -$1.7B | -152.1% | $265M | -$23.44 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.